Eli Lilly and Company (NYSE:LLY) Stake Boosted by Indie Asset Partners LLC


Share on StockTwits

Indie Asset Partners LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 69,033 shares of the company’s stock after acquiring an additional 340 shares during the period. Eli Lilly and accounts for 13.6% of Indie Asset Partners LLC’s investment portfolio, making the stock its biggest holding. Indie Asset Partners LLC’s holdings in Eli Lilly and were worth $11,656,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of LLY. Fisher Asset Management LLC boosted its holdings in Eli Lilly and by 7.7% in the fourth quarter. Fisher Asset Management LLC now owns 5,037,790 shares of the company’s stock worth $850,580,000 after purchasing an additional 359,479 shares in the last quarter. California Public Employees Retirement System boosted its holdings in Eli Lilly and by 2.5% in the fourth quarter. California Public Employees Retirement System now owns 4,575,362 shares of the company’s stock worth $772,504,000 after purchasing an additional 110,280 shares in the last quarter. UBS Asset Management Americas Inc. boosted its holdings in Eli Lilly and by 1.9% in the third quarter. UBS Asset Management Americas Inc. now owns 4,428,133 shares of the company’s stock worth $655,452,000 after purchasing an additional 83,647 shares in the last quarter. Morgan Stanley boosted its holdings in Eli Lilly and by 9.7% in the third quarter. Morgan Stanley now owns 3,012,938 shares of the company’s stock worth $445,978,000 after purchasing an additional 265,526 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. boosted its holdings in Eli Lilly and by 2.8% in the third quarter. Robeco Institutional Asset Management B.V. now owns 2,659,829 shares of the company’s stock worth $393,707,000 after purchasing an additional 72,670 shares in the last quarter. Institutional investors and hedge funds own 75.59% of the company’s stock.

LLY has been the subject of a number of recent research reports. Mizuho upped their price objective on shares of Eli Lilly and from $222.00 to $228.00 and gave the stock a “buy” rating in a report on Monday, February 1st. Morgan Stanley upped their price target on shares of Eli Lilly and from $190.00 to $217.00 and gave the company an “overweight” rating in a report on Thursday, February 4th. Barclays upped their price target on shares of Eli Lilly and from $190.00 to $232.00 and gave the company an “overweight” rating in a report on Monday, February 1st. Truist upped their price target on shares of Eli Lilly and from $200.00 to $215.00 in a report on Monday, February 1st. Finally, Bank of America upped their price target on shares of Eli Lilly and from $195.00 to $225.00 and gave the company a “buy” rating in a report on Friday, January 22nd. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $190.31.

Shares of LLY traded up $0.88 during trading hours on Tuesday, reaching $201.56. 56,785 shares of the company traded hands, compared to its average volume of 4,843,328. The stock’s fifty day moving average is $195.97 and its 200 day moving average is $161.62. The stock has a market cap of $193.18 billion, a P/E ratio of 32.79, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37. The company has a debt-to-equity ratio of 3.27, a quick ratio of 1.06 and a current ratio of 1.36. Eli Lilly and Company has a 1-year low of $117.06 and a 1-year high of $218.00.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Thursday, January 28th. The company reported $2.75 EPS for the quarter, beating the Zacks’ consensus estimate of $2.35 by $0.40. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The business had revenue of $7.44 billion during the quarter, compared to analyst estimates of $7.27 billion. During the same quarter in the prior year, the business earned $1.73 earnings per share. The firm’s revenue for the quarter was up 21.7% on a year-over-year basis. On average, equities research analysts predict that Eli Lilly and Company will post 7.56 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 10th. Investors of record on Friday, February 12th will be given a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 1.69%. The ex-dividend date of this dividend is Thursday, February 11th. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.74. Eli Lilly and’s dividend payout ratio is 56.29%.

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction dated Wednesday, January 13th. The shares were sold at an average price of $185.97, for a total value of $39,053,700.00. Following the completion of the transaction, the insider now owns 110,807,418 shares of the company’s stock, valued at $20,606,855,525.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.09% of the company’s stock.

Eli Lilly and Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia.

Featured Story: What’s a Black Swan?

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.